• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Adagio Medical Holdings Inc

    3/27/25 5:26:44 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care
    Get the next $ADGM alert in real time by email
    S-8 1 tm2510632d1_s8.htm FORM S-8

    As filed with the Securities and Exchange Commission on March 27, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Adagio Medical Holdings, Inc.

     

    (Exact name of Registrant as specified in its charter)

     

     

         
    Delaware   99-1151466

    (State or other jurisdiction of

    incorporation or organization)

     

     

    (I.R.S. Employer

    Identification Number)

     

       

    26051 Merit Circle, Suite 102

    Laguna Hills, California

      92653
    (Address of Principal Executive Offices)   (Zip Code)

     

     

     

    Adagio Medical Holdings, Inc. 2024 Equity Incentive Plan

    (Full Title of the Plans)

     

     

     

    Todd Usen

    Chief Executive Officer

    Adagio Medical Holdings, Inc.

    26051 Merit Circle, Suite 102

    Laguna Hills, California 92653

    (949) 348-1188

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Michael S. Lee, Esq.

    Reed Smith LLP

    599 Lexington Ave

    New York, NY 10022

    Telephone: (212) 549 0204

     

    Michael Sanders, Esq.

    Reed Smith LLP

    1901 Avenue of the Stars, Suite 700

    Los Angeles, CA 90067

    Telephone: (310) 734 5232

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  ¨   Accelerated filer   ¨
    Non-accelerated filer  x   Smaller reporting company   x
          Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (the “Registration Statement”) is being filed to register an additional 1,725,144 shares of common stock, par value $0.0001 per share (the “Common Stock”) of Adagio Medical Holdings, Inc. (the “Registrant”), reserved for issuance pursuant to future awards under the Registrant’s 2024 Equity Incentive Plan (the “2024 Plan”) as a result of the annual evergreen increase under the 2024 Plan. Such shares of Common Stock are in addition to the 4,472,593 shares of Common Stock already issuable under the 2024 Plan as registered on the Registrant’s Form S-8 filed with the Securities and Exchange Commission on October 8, 2024 (File No. 333-282544) (the “Prior Registration Statement”).

     

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statement relates, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    In this registration statement, Adagio Medical Holdings, Inc. is sometimes referred to as “Registrant,” “we,” “us,” or “our.”

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents previously filed by the Registrant with the Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

     

    (a) The Registrant’s Current Report on Form 8-K filed with the Commission on August 6, 2024 (except for Item 7.01) (as amended on August 14, 2024 and November 4, 2024), November 1, 2024, December 16, 2024, December 23, 2024, January 6, 2025 and February 5, 2025; and

     

    (b) The Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 27, 2025.

     

    (c) The Company’s Quarterly Reports on Form 10-Q for the quarter ended June 30, 2024, filed with the Commission on August 26, 2024, and for the quarter ended September 30, 2024, filed with the Commission on November 14, 2024.

     

    (d) The description of the Registrant’s Common Stock which is contained in a registration statement on Form 8-A filed with the Commission on August 1, 2024 (File No. 001-42199) under the Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

     

     

     

     

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this registration statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

     

     

     

    Item 8. Exhibits.

     

    Reference is made under this Item 8 to the exhibit index included in this Registration Statement.

     

    Exhibit Index

     

    Exhibit
    Number
      Exhibit Description
         
    4.1   Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on August 6, 2024).
         
    4.2   Amended and Restated By-Laws of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on August 6, 2024).
       
    4.3   Specimen Common Stock Certificate of Registrant (incorporated herein by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K filed with the Commission on August 6, 2024).
         
    4.4   Registrant's 2024 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed with the Commission on August 6, 2024).
         
    5.1*   Opinion of Reed Smith LLP.
       
    23.1*   Consent of WithumSmith+Brown, PC, independent registered public accounting firm for Adagio Medical Holdings, Inc.
       
    23.4*   Consent of Reed Smith LLP (included as part of Exhibit 5.1).
       
    24.1*   Power of Attorney (included on the signature page hereto).
       
    107*   Filing Fee Table.
       

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Laguna Hills, State of California, on this 27th day of March, 2025.

     

        Adagio Medical Holdings, Inc.
         
      By: /s/ Todd Usen
        Todd Usen
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Todd Usen and John Dahldorf and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             

     

    /s/ Todd Usen

     

    Chief Executive Officer and Director

    (Principal Executive Officer)

      March 27, 2025
    Todd Usen        
             
    /s/ John Dahldorf   Chief Financial Officer   March 27, 2025

    John Dahldorf

      (Principal Financial and Accounting Officer)    
             
    /s/ James L. Cox   Director   March 27, 2025

    James L. Cox

     

           
             
    /s/ Orly Mishan   Director   March 27, 2025

    Orly Mishan

     

           
             
    /s/ Keyvan Mirsaeedi-Farahani   Director   March 27, 2025

    Keyvan Mirsaeedi-Farahani

     

           
             
    /s/ Timothy Moran   Director   March 27, 2025

    Timothy Moran

           
             
    /s/ Sandra Gardiner   Director   March 27, 2025
    Sandra Gardiner        

     

     

     

    Get the next $ADGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGM

    DatePrice TargetRatingAnalyst
    12/2/2025$4.00Buy
    Lake Street
    More analyst ratings

    $ADGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Adagio Medical Holdings with a new price target

    Lake Street initiated coverage of Adagio Medical Holdings with a rating of Buy and set a new price target of $4.00

    12/2/25 8:38:52 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference

    Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA. Presentation Information A live webcast and replay of the session will be accessible at https://event.summitcast.com or on the Company's website at https://investors.adagiomedical.com. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel,

    2/20/26 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Small Cap Growth Virtual Investor Conference: Presentations Now Available for On-Demand Viewing

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small Cap Growth Virtual Investor Conference, held February 5th are now available for on-demand viewing. Individual investors, institutional investors, advisors, and analysts are invited to attend.REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through February 10th. Please Schedule 1x1 Meetings here Febru

    2/6/26 8:35:00 AM ET
    $ADGM
    $COCH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia

    Early Feasibility Outcomes in a Real-World Patient Cohort of Both Ischemic and Challenging Non-Ischemic Patients Published in Circulation: Arrhythmia and Electrophysiology Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study ("EFS") evaluating ultralow temperature cardiac ablation ("ULTC") for the treatment of scar-related ventricular tachycardia ("VT"). The study was published in Circulation: Arrythmia and Electrophysiology. The prospective, multi-center study was conducted under the U.S. Food

    2/4/26 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kaster Deborah bought $17,973 worth of shares (15,000 units at $1.20) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/18/25 6:00:11 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Usen Todd bought $225,973 worth of shares (207,315 units at $1.09) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/15/25 9:24:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Salmon Sean

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/11/25 9:51:26 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Adagio Medical Holdings Inc

    SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    2/17/26 8:13:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Adagio Medical Holdings Inc

    SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    2/17/26 4:32:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc

    SCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    2/17/26 4:00:03 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kaster Deborah bought $17,973 worth of shares (15,000 units at $1.20) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/18/25 6:00:11 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Usen Todd bought $225,973 worth of shares (207,315 units at $1.09) (SEC Form 4)

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    12/15/25 9:24:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Leadership Updates

    Live Leadership Updates

    View All

    Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness

    Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. "These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology ("ULTC") for electrophys

    12/22/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

    Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company's Audit Committee and Compensation Committee. Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company's cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic's Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Abl

    12/11/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    11/13/24 4:30:17 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    8/12/24 4:22:57 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care